Amyloidosis with IgM monoclonal gammopathies

Morie Gertz, Robert A. Kyle

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We sought to review outcomes of patients who have immunoglobulin light-chain amyloidosis of the IgM type. Fifty patients with a serum IgM monoclonal protein and biopsy-proven amyloid were evaluated. The percentages of patients presenting with cardiac, renal, hepatic, and pulmonary amyloid were 44%, 32%, 14%, and 10%, respectively. Forty-two percent had an M-protein spike in the serum greater than 1.5 g/dL, and 14% had an IgM peak greater than 3 g/dL. Amyloidosis was diagnosed easily by biopsies of the subcutaneous fat, rectum, and bone marrow, which demonstrated deposits in 84%, 72%, and 50%, respectively. The median survival of all patients was 24.6 months. Fifty-three percent of all deaths were due to cardiac amyloidosis. Twelve percent died of respiratory failure, and 7% each died of macroglobulinemia, hepatic failure, and renal failure. Of the 22 patients with amyloid cardiomyopathy, the median survival was 11.1 months and fewer than 10% survived 5 years. Of the 28 patients without amyloid cardiomyopathy at diagnosis, the median survival was 27 months, with approximately 30% surviving 5 years. We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival.

Original languageEnglish (US)
Pages (from-to)325-328
Number of pages4
JournalSeminars in Oncology
Volume30
Issue number2
DOIs
StatePublished - Jan 1 2003

Fingerprint

Paraproteinemias
Amyloidosis
Immunoglobulin M
Amyloid
Cardiomyopathies
Survival
Immunoglobulin Light Chains
Biopsy
Waldenstrom Macroglobulinemia
Subcutaneous Fat
Liver Failure
Serum
Rectum
Respiratory Insufficiency
Renal Insufficiency
Creatinine
Proteins
Bone Marrow
Kidney
Lung

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Amyloidosis with IgM monoclonal gammopathies. / Gertz, Morie; Kyle, Robert A.

In: Seminars in Oncology, Vol. 30, No. 2, 01.01.2003, p. 325-328.

Research output: Contribution to journalArticle

Gertz, Morie ; Kyle, Robert A. / Amyloidosis with IgM monoclonal gammopathies. In: Seminars in Oncology. 2003 ; Vol. 30, No. 2. pp. 325-328.
@article{bab306332a2141e38359b922dc3d588a,
title = "Amyloidosis with IgM monoclonal gammopathies",
abstract = "We sought to review outcomes of patients who have immunoglobulin light-chain amyloidosis of the IgM type. Fifty patients with a serum IgM monoclonal protein and biopsy-proven amyloid were evaluated. The percentages of patients presenting with cardiac, renal, hepatic, and pulmonary amyloid were 44{\%}, 32{\%}, 14{\%}, and 10{\%}, respectively. Forty-two percent had an M-protein spike in the serum greater than 1.5 g/dL, and 14{\%} had an IgM peak greater than 3 g/dL. Amyloidosis was diagnosed easily by biopsies of the subcutaneous fat, rectum, and bone marrow, which demonstrated deposits in 84{\%}, 72{\%}, and 50{\%}, respectively. The median survival of all patients was 24.6 months. Fifty-three percent of all deaths were due to cardiac amyloidosis. Twelve percent died of respiratory failure, and 7{\%} each died of macroglobulinemia, hepatic failure, and renal failure. Of the 22 patients with amyloid cardiomyopathy, the median survival was 11.1 months and fewer than 10{\%} survived 5 years. Of the 28 patients without amyloid cardiomyopathy at diagnosis, the median survival was 27 months, with approximately 30{\%} surviving 5 years. We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival.",
author = "Morie Gertz and Kyle, {Robert A.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1053/sonc.2003.50060",
language = "English (US)",
volume = "30",
pages = "325--328",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Amyloidosis with IgM monoclonal gammopathies

AU - Gertz, Morie

AU - Kyle, Robert A.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We sought to review outcomes of patients who have immunoglobulin light-chain amyloidosis of the IgM type. Fifty patients with a serum IgM monoclonal protein and biopsy-proven amyloid were evaluated. The percentages of patients presenting with cardiac, renal, hepatic, and pulmonary amyloid were 44%, 32%, 14%, and 10%, respectively. Forty-two percent had an M-protein spike in the serum greater than 1.5 g/dL, and 14% had an IgM peak greater than 3 g/dL. Amyloidosis was diagnosed easily by biopsies of the subcutaneous fat, rectum, and bone marrow, which demonstrated deposits in 84%, 72%, and 50%, respectively. The median survival of all patients was 24.6 months. Fifty-three percent of all deaths were due to cardiac amyloidosis. Twelve percent died of respiratory failure, and 7% each died of macroglobulinemia, hepatic failure, and renal failure. Of the 22 patients with amyloid cardiomyopathy, the median survival was 11.1 months and fewer than 10% survived 5 years. Of the 28 patients without amyloid cardiomyopathy at diagnosis, the median survival was 27 months, with approximately 30% surviving 5 years. We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival.

AB - We sought to review outcomes of patients who have immunoglobulin light-chain amyloidosis of the IgM type. Fifty patients with a serum IgM monoclonal protein and biopsy-proven amyloid were evaluated. The percentages of patients presenting with cardiac, renal, hepatic, and pulmonary amyloid were 44%, 32%, 14%, and 10%, respectively. Forty-two percent had an M-protein spike in the serum greater than 1.5 g/dL, and 14% had an IgM peak greater than 3 g/dL. Amyloidosis was diagnosed easily by biopsies of the subcutaneous fat, rectum, and bone marrow, which demonstrated deposits in 84%, 72%, and 50%, respectively. The median survival of all patients was 24.6 months. Fifty-three percent of all deaths were due to cardiac amyloidosis. Twelve percent died of respiratory failure, and 7% each died of macroglobulinemia, hepatic failure, and renal failure. Of the 22 patients with amyloid cardiomyopathy, the median survival was 11.1 months and fewer than 10% survived 5 years. Of the 28 patients without amyloid cardiomyopathy at diagnosis, the median survival was 27 months, with approximately 30% surviving 5 years. We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival.

UR - http://www.scopus.com/inward/record.url?scp=0037397348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037397348&partnerID=8YFLogxK

U2 - 10.1053/sonc.2003.50060

DO - 10.1053/sonc.2003.50060

M3 - Article

C2 - 12720162

AN - SCOPUS:0037397348

VL - 30

SP - 325

EP - 328

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -